Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference

BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq.

GlobeNewsWire • 11 hours ago

Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy

BRISBANE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it will host an in-person and virtual key opinion leader (KOL) event in New York on Wednesday, March 18, 2026, with presentations at 2:00 PM ET and a reception at 4:00 PM ET.

GlobeNewsWire • Feb 17, 2026

Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated Diseases

Annexon offers high-risk, high-reward potential with its C1q-targeted pipeline, led by tanruprubart for GBS and vonaprument for geographic atrophy. Tanruprubart's Phase III results are promising, but there is U.S. regulatory uncertainty due to non-U.S. trial sites and dose-response questions. Vonaprument's Phase III trial focuses on vision preservation, potentially differentiating ANNX in the competitive but large geographic atrophy market.

Seeking Alpha • Jan 24, 2026

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on January 9, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

GlobeNewsWire • Jan 16, 2026

Annexon, Inc. (ANNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Annexon, Inc. (ANNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 14, 2026

Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026

Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for  Guillain-Barré Syndrome ( GBS); BLA Submission with U.S./European Data Planned in 2026

GlobeNewsWire • Jan 12, 2026

Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome

Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of Care BLA Submission with U.S./European Data from FORWARD Trial Planned in 2026 BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for tanruprubart for the treatment of Guillain-Barré syndrome (GBS).

GlobeNewsWire • Jan 8, 2026

Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, president and chief executive officer, will present at the 44th Annual J.P.

GlobeNewsWire • Jan 7, 2026

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on December 10, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).

GlobeNewsWire • Dec 17, 2025

Annexon: Maintaining "Buy" Rating On Second C1q Inhibitor Advancement For Geographic Atrophy

Annexon Inc. (ANNX) is still a "Buy" in my view, driven by progress in its c1q inhibitor pipeline for rare diseases. ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA discussions. Vonaprument, targeting dry age-related macular degeneration patients with geographic atrophy, is in phase 3 testing with topline data expected in 2nd half of 2026.

Seeking Alpha • Nov 20, 2025